메뉴 건너뛰기




Volumn 27, Issue 10, 2007, Pages 1379-1386

Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy

Author keywords

Antiretroviral; Drug interactions; HIV; Human immunodeficiency virus; Prevalence; Risk factors

Indexed keywords

AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATORVASTATIN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; FLUTICASONE; HISTAMINE H2 RECEPTOR ANTAGONIST; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RIFABUTIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SILDENAFIL; STAVUDINE; TADALAFIL; TENOFOVIR; UNINDEXED DRUG; VARDENAFIL; VORICONAZOLE; ZIDOVUDINE;

EID: 34948865262     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.10.1379     Document Type: Article
Times cited : (85)

References (33)
  • 1
    • 0033739530 scopus 로고    scopus 로고
    • Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884
    • Fletcher CV, Acosta EP, Cheng H, et al. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884. AIDS 2000;14:2495-501.
    • (2000) AIDS , vol.14 , pp. 2495-2501
    • Fletcher, C.V.1    Acosta, E.P.2    Cheng, H.3
  • 2
    • 21544472342 scopus 로고    scopus 로고
    • Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: Results of AIDS clinical trials group 5108 study
    • Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS clinical trials group 5108 study. J Acquir Immune Defic Syndr 2005;39:307-12.
    • (2005) J Acquir Immune Defic Syndr , vol.39 , pp. 307-312
    • Gerber, J.G.1    Rosenkranz, S.L.2    Fichtenbaum, C.J.3
  • 3
    • 0033237706 scopus 로고    scopus 로고
    • Effect of indinavir on the single-dose pharmacokinetics of theophylline in healthy subjects
    • Mistry GC, Laurent A, Sterrett AT, Deutsch PJ. Effect of indinavir on the single-dose pharmacokinetics of theophylline in healthy subjects. J Clin Pharmacol 1999;39:636-42.
    • (1999) J Clin Pharmacol , vol.39 , pp. 636-642
    • Mistry, G.C.1    Laurent, A.2    Sterrett, A.T.3    Deutsch, P.J.4
  • 4
    • 27844461529 scopus 로고    scopus 로고
    • Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: Final results of the EFADITE trial
    • Barrios A, Negredo E, Domingo P, et al. Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial. Antivir Ther 2005;10:825-32.
    • (2005) Antivir Ther , vol.10 , pp. 825-832
    • Barrios, A.1    Negredo, E.2    Domingo, P.3
  • 5
    • 34948889656 scopus 로고    scopus 로고
    • Kaul S, Bassi K, Damle B, et al. Pharmacokinetic evaluation of the combination of atazanavir, enteric coated didanosine, and tenofovir disoproxil fumarate for a once-daily antiretroviral regimen [abstract]. In: Program and abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2003:abstract A-1616.
    • Kaul S, Bassi K, Damle B, et al. Pharmacokinetic evaluation of the combination of atazanavir, enteric coated didanosine, and tenofovir disoproxil fumarate for a once-daily antiretroviral regimen [abstract]. In: Program and abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2003:abstract A-1616.
  • 6
    • 34948898449 scopus 로고    scopus 로고
    • Van Lunzen J, Schewe K, Kuhlmann B. High rate of virological failure during once-daily therapy with tenofovir + didanosine 250 mg + efavirenz in antiretroviral-naïve patients: results of the 12 week interim analysis of the TEDDI trial [abstract]. In: Program and abstracts of the 3rd International AIDS Society conference on HIV pathogenesis and treatment. Washington, DC: American Society for Microbiology, 2005:abstract TuPp0306.
    • Van Lunzen J, Schewe K, Kuhlmann B. High rate of virological failure during once-daily therapy with tenofovir + didanosine 250 mg + efavirenz in antiretroviral-naïve patients: results of the 12 week interim analysis of the TEDDI trial [abstract]. In: Program and abstracts of the 3rd International AIDS Society conference on HIV pathogenesis and treatment. Washington, DC: American Society for Microbiology, 2005:abstract TuPp0306.
  • 7
    • 20144365012 scopus 로고    scopus 로고
    • Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results
    • Kashuba AD, Tierney C, Downey GF, et al. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS 2005;19:145-52.
    • (2005) AIDS , vol.19 , pp. 145-152
    • Kashuba, A.D.1    Tierney, C.2    Downey, G.F.3
  • 8
    • 34948860470 scopus 로고    scopus 로고
    • Adkison K, Fang L, Shachoy-Clark A, et al. The pharmacokinetic inieraction between entry inhibitor 873140 and efavirenz in healthy adults [abstract]. In: Program and abstracts of the 45th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2005:abstract A-1197.
    • Adkison K, Fang L, Shachoy-Clark A, et al. The pharmacokinetic inieraction between entry inhibitor 873140 and efavirenz in healthy adults [abstract]. In: Program and abstracts of the 45th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2005:abstract A-1197.
  • 10
    • 0027122957 scopus 로고
    • revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
    • Centers for Disease Control and Prevention
    • Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41:1-19.
    • (1993) MMWR Recomm Rep 1992 , vol.41 , pp. 1-19
  • 11
    • 34948847484 scopus 로고    scopus 로고
    • Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents - October 6
    • United States Department of Health and Human Services, //. Accessed December 5, 2006
    • United States Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents - October 6, 2005. Available from htip://www.AIDSinfo.NIH.gov. Accessed December 5, 2006.
    • (2005) Available from htip
  • 12
    • 34948851207 scopus 로고    scopus 로고
    • Abbott Laboratories. Kaletra (lopinavir/ritonavir) package insert. Abboit Park, IL; 2006
    • Abbott Laboratories. Kaletra (lopinavir/ritonavir) package insert. Abboit Park, IL; 2006.
  • 13
    • 34948857334 scopus 로고    scopus 로고
    • Abbott Laboratories. Norvir (ritonavir) package insert. Abboit Park, IL; 2006
    • Abbott Laboratories. Norvir (ritonavir) package insert. Abboit Park, IL; 2006.
  • 14
    • 34948882183 scopus 로고    scopus 로고
    • Agouron Pharmaceuticals INC. Rescriptor (delavirdine) package insert. La Jolla, CA; 2006
    • Agouron Pharmaceuticals INC. Rescriptor (delavirdine) package insert. La Jolla, CA; 2006.
  • 15
    • 34948836643 scopus 로고    scopus 로고
    • Agouron Pharmaceuticals INC. Viracept (nelfinavir) package insert. La Jolla, CA; 2006
    • Agouron Pharmaceuticals INC. Viracept (nelfinavir) package insert. La Jolla, CA; 2006.
  • 16
    • 34948881081 scopus 로고    scopus 로고
    • Boehringer Ingelheim GmbH. Aptivus (tipranavir) package insert. Ingelheim, Germany; 2006
    • Boehringer Ingelheim GmbH. Aptivus (tipranavir) package insert. Ingelheim, Germany; 2006.
  • 17
    • 34948848489 scopus 로고    scopus 로고
    • Boehringer Ingelheim GmbH. Viramune (nevirapine) package insert. Ingelheim, Germany; 2005
    • Boehringer Ingelheim GmbH. Viramune (nevirapine) package insert. Ingelheim, Germany; 2005.
  • 18
    • 34948866130 scopus 로고    scopus 로고
    • Bristol-Myers Squibb. Reyataz (atazanavir) package insert. Princeton, NJ; 2006
    • Bristol-Myers Squibb. Reyataz (atazanavir) package insert. Princeton, NJ; 2006.
  • 19
    • 34948893313 scopus 로고    scopus 로고
    • Bristol-Myers Squibb. Videx EC (didanosine EC) package insert. Princeton, NJ; 2006
    • Bristol-Myers Squibb. Videx EC (didanosine EC) package insert. Princeton, NJ; 2006.
  • 20
    • 34948873537 scopus 로고    scopus 로고
    • Bristol-Myers Squibb. Zerit (stavudine) package insert. Princeton, NJ; 2006
    • Bristol-Myers Squibb. Zerit (stavudine) package insert. Princeton, NJ; 2006.
  • 21
    • 34948907757 scopus 로고    scopus 로고
    • Gilead Sciences. Emtriva (emtricitabine) package insert. Foster City, CA; 2006
    • Gilead Sciences. Emtriva (emtricitabine) package insert. Foster City, CA; 2006.
  • 22
    • 34948820548 scopus 로고    scopus 로고
    • Gilead Sciences. Viread (lenofovir) package insert. Foster City, CA; 2006
    • Gilead Sciences. Viread (lenofovir) package insert. Foster City, CA; 2006.
  • 23
    • 34948882184 scopus 로고    scopus 로고
    • GlaxoSmithKline. Epivir (lamivudine) package insert. Research Triangle Park, NC; 2006
    • GlaxoSmithKline. Epivir (lamivudine) package insert. Research Triangle Park, NC; 2006.
  • 24
    • 34948900753 scopus 로고    scopus 로고
    • GlaxoSmithKline. Lexiva (fosamprenavir) package insert. Research Triangle Park, NC; 2006
    • GlaxoSmithKline. Lexiva (fosamprenavir) package insert. Research Triangle Park, NC; 2006.
  • 25
    • 34948910559 scopus 로고    scopus 로고
    • GlaxoSmithKline. Retrovir (zidovudine) package insert. Research Triangle Park, NC; 2006
    • GlaxoSmithKline. Retrovir (zidovudine) package insert. Research Triangle Park, NC; 2006.
  • 26
    • 34948898450 scopus 로고    scopus 로고
    • GlaxoSmithKline. Ziagen (abacavir) package insert. Research Triangle Park, NC; 2006
    • GlaxoSmithKline. Ziagen (abacavir) package insert. Research Triangle Park, NC; 2006.
  • 27
    • 34948872454 scopus 로고    scopus 로고
    • Merck & Co, Inc. Crixivan (indinavir) package insert. Whitehouse Station, NJ; 2006
    • Merck & Co, Inc. Crixivan (indinavir) package insert. Whitehouse Station, NJ; 2006.
  • 28
    • 34948835074 scopus 로고    scopus 로고
    • Roche Pharmaceuticals. Fuzeon (enfuvirtide) package insert. Nutley, NJ; 2006
    • Roche Pharmaceuticals. Fuzeon (enfuvirtide) package insert. Nutley, NJ; 2006.
  • 29
    • 34948859951 scopus 로고    scopus 로고
    • Roche Pharmaceuticals. Invirase (saquinavir mesylate) package insert. Nutley, NJ; 006
    • Roche Pharmaceuticals. Invirase (saquinavir mesylate) package insert. Nutley, NJ; 006.
  • 30
    • 0004301834 scopus 로고    scopus 로고
    • Internet database. Greenwood Village, CO
    • Micromedex Healthcare Series. Internet database. Greenwood Village, CO, 2007.
    • (2007) Micromedex Healthcare Series
  • 32
    • 0032822545 scopus 로고    scopus 로고
    • Antiretroviral medication errors for patients with HIV infection
    • Purdy BD, Lesar TS. Antiretroviral medication errors for patients with HIV infection. AIDS Read 1999;9:414-19.
    • (1999) AIDS Read , vol.9 , pp. 414-419
    • Purdy, B.D.1    Lesar, T.S.2
  • 33
    • 33748663517 scopus 로고    scopus 로고
    • Antiretroviral medication errors among hospitalized patients with HIV infection
    • Rastegar DA, Knight AM, Monolakis JS. Antiretroviral medication errors among hospitalized patients with HIV infection. Clin Infect Dis 2006;43:933-8.
    • (2006) Clin Infect Dis , vol.43 , pp. 933-938
    • Rastegar, D.A.1    Knight, A.M.2    Monolakis, J.S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.